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Abstract
Background: The study aim was to estimate the proportion of acromegaly patients with various comorbidities and
to determine if biochemical control was associated with reduced proportion of cardiovascular risk factors.
Methods: Data were from a single-center acromegaly registry. Study patients were followed for ≥12 months after
initial treatment. Study period was from first to last insulin-like growth factor-I and growth hormone tests.
Results: Of 121 patients, 55% were female. Mean age at diagnosis was 42.4 (SD: 15.0). Mean study period was 8.8
(SD: 7.2) years. Macroadenomas were observed in 93 of 106 patients (87.7%), and microadenomas in 13 (12.3%).
Initial treatment was surgery in 104 patients (86%), pharmacotherapy in 16 (13.2%), and radiation therapy in 1
(0.8%). Of 120 patients, 79 (65.8%) achieved control during the study period. New onset comorbidities (reported
6 months after study start) were uncommon (<10%). Comorbidities were typically more prevalent in uncontrolled
versus controlled patients—24 (58.5%) vs. 33 (41.8%) had hypertension, 17 (41.5%) vs. 20 (25.3%) had diabetes, 11
(26.8%) vs. 16 (20.3%) had sleep apnea, and 3 (7.3%) vs. 3 (3.8%) had cardiomyopathy—except for colon polyps or
cancer (19.5% vs. 20.3%), left ventricular hypertrophy (9.8% vs. 11.4%), and visual defects (14.6% vs. 17.7%).
Conclusions: A greater number of comorbidities were observed in biochemically uncontrolled patients with
acromegaly compared to their controlled counterparts in this single-center registry. About a third of the patients
remained uncontrolled after a mean of >8 years of treatment, demonstrating the difficulty of achieving control in
some patients.
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Background
Acromegaly results from excessive growth hormone
(GH) production, usually caused by a benign pituitary
adenoma. GH has direct metabolic effects and also stim-
ulates hepatic insulin-like growth factor-I (IGF-1) pro-
duction. IGF-1 in turn facilitates somatic growth and
metabolic function [1]. The disease affects between 40
and 130 individuals per million persons, or approxi-
mately 20,000 people in the US [2], and recent studies
indicate incidence of pituitary tumors in the US is in-
creasing [3]. Although untreated acromegaly has
clinically significant consequences, most signs and symp-
toms appear slowly, often resulting in delayed diagnosis.
Most acromegaly patients are diagnosed at an average
age of about 40 years [2, 4]. Diagnosis is made clinically
on the basis of typical signs and symptoms and con-
firmed with laboratory assessment of GH and/or IGF-1
levels.
The primary goal of therapy is to normalize GH and
IGF-1 levels, as these values have been shown to corres-
pond to a reduction in mortality similar to that of an un-
affected population [5, 6]. Initial treatment is generally
transsphenoidal surgical resection of the adenoma, but
about half of the patients require additional treatment [7].
Current guidelines recommend somatostatin receptor li-
gands (SRLs) (octreotide and lanreotide) or GH-receptor
* Correspondence: dasha@pharllc.com
2Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404,
Beverly Hills, CA 90212, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Carmichael et al. BMC Endocrine Disorders  (2017) 17:15 
DOI 10.1186/s12902-017-0166-6
antagonist pegvisomant for initial medical therapy in pa-
tients with moderate-to-severe signs and symptoms of
GH excess. In patients with very mild signs and symp-
toms, guidelines suggest an initial trial of the dopamine
agonist cabergoline [7, 8].
In addition to direct effects from the tumor mass, un-
treated patients with acromegaly may develop diabetes
mellitus, hypertension, cardiomyopathy, sleep apnea, and
colon polyps at rates much higher than the non-
acromegaly population [9]. The risk of developing these
comorbid conditions generally increases with the length
and severity of biochemical abnormalities. Successful
treatment appears to reduce myocardial thickness [10]
and improve sleep apnea [11], but a link between bio-
chemical control and hypertension, diabetes, and other
key outcomes has not been established. We sought,
using medical records from a single referral center, to
estimate the proportion of acromegaly patients with
various comorbid conditions, and to determine if bio-
chemical disease control was associated with reduced
rate of cardiovascular risk factors.
Methods
This was a prospective cohort study of an acromegaly
registry established at the Cedars-Sinai Medical Center
Pituitary Center (CSMC-PC), with retrospective chart
data at CSMC-PC for some patients dating as far back
as 1985. Consenting patients had data abstracted from
medical records and entered in a database. This registry
contains data on demographics, medical and surgical
therapy, symptoms, laboratory values, cardiology and
colonoscopy results, pathology, radiology, surgical infor-
mation, and visual field data. The database is updated
periodically. The current study focused on acromegaly pa-
tients treated at the center from 1985 through June 2013.
Registry participants followed for at least 12 months after
initial treatment were eligible for inclusion in the current
study. The first and last values for IGF-1 and GH tests for
each patient were used to define the study start and end
dates. The study was approved by the CSMC Institutional
Review Board.
Baseline measures, determined in the 6 months follow-
ing the first recorded biochemical test, included patient
demographics (age, sex, and race/ethnicity), tumor size,
and presence of hormonal abnormalities (prolactin ele-
vation [hyperprolactinemia], adrenal insufficiency [use of
adrenal replacement], gonadal insufficiency [use of sex
steroid replacement], and hypothyroidism [use of thyroid
replacement]). Adrenal insufficiency was diagnosed with
standard cortrosyn (ACTH) stimulation testing with a
cutoff point of 18 mcg/dl. Treatments for acromegaly,
including surgery, radiation, and pharmacotherapy, were
recorded, as were the dates of those treatments. Patients
receiving presurgical pharmacotherapy of short duration
were reported simply as having had surgery, unless
pharmacotherapy was continued after the procedure.
The presence of comorbid conditions, including hyper-
tension (i.e., diagnosis of hypertension or use of hyper-
tensive medication), diabetes (i.e., diagnosis of diabetes
or HbA1c ≥6.5% or use of antihyperglycemic medica-
tion), left ventricular hypertrophy (LVH), cardiomyop-
athy, congestive heart failure (CHF), sleep apnea, colon
polyps, colon cancer, and visual field defects (i.e., diagno-
sis of any visual acuity impairment or visual field cut),
was recorded, as was the use of antihypertensive and
antihyperglycemic medications. All comorbidities were
diagnosed by specialists in their respective fields, using
standard diagnostic methods. All GH and IGF-1 values
were recorded. The primary predictor variable was bio-
chemical control at study end, defined as a last IGF-1
less than or equal to the upper limit of normal for pa-
tient’s age and gender [12, 13]. Considering the possiblity
of discordance between values of GH and IGF-I in dif-
ferent treatment scenarios, to maintain a robust defin-
ition of control we opted to rely solely on IGF-I for this
analysis [13]. The primary and secondary outcomes of
interest were the proportion of patients with new onset
(noted any time after the first 6 months of observation)
comorbidities and the proportion with a comorbidity of
interest at any time during the study period.
Descriptive statistics, including means, standard devia-
tions (SD), medians, and percentages, were estimated for
all study measures as applicable, and reported separately
for patients who did and did not achieve biochemical
control. For the primary analysis, presence of existing
and new onset comorbidities were examined in patients,
stratified on the basis of whether or not they had
attained biochemical control. All data transformations
and statistical analyses were performed using SAS® ver-
sion 9.4 (SAS Institute, Cary, NC).
Results
A total of 121 acromegaly patients met the inclusion cri-
teria, provided written consent, and were included in the
study. The mean (SD) patient age at the time of this
study was 55.4 (16.7) years, and the mean age at diagno-
sis was 42.4 (15.0). Overall, 67 (55%) patients were fe-
male. Race/ethnicity was reported as Caucasians for 88
(72.7%) patients, Asian for 16 (13.2%), and Hispanic for
12 (9.9%); 5 (4.1%) patients were of other race/ethnicity.
The mean (SD) time from first to last recorded bio-
chemical value (study period) was 8.8 (7.2) years, and
the median (25th to 75th percentile) was 5.8 (3.2-13.7)
years. For 106 patients, data were available on initial
tumor size. Macroadenomas were observed in 93 pa-
tients (87.7%) and microadenomas in 13 patients (12.3%)
in this cohort. On presentation, 20 (16.5%) patients had
gonadal insufficiency, 19 (15.7%) had hypothyroidism, 18
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(14.9%) had adrenal insufficiency, and 1 (0.8%) had ele-
vated prolactin (Table 1).
Initial treatment was surgery, observed in 104 patients
(86%), which included 13 patients with short duration
pre-surgical pharmacologic therapy. Initial treatment
was pharmacologic in 16 patients (13.2%), and radiation
therapy in the 1 remaining patient. For patients treated
with primary medical therapy, somatostatin analogues
were the most common initial pharmacologic treatment,
observed in 11 patients (9.1%), followed by dopamine ago-
nists in 5 patients (4.1%) (Table 2). By the end of a median
of 5.8 years of follow-up, 92 (76%) patients had been
treated with multiple modalities. Of 104 initially surgically
treated patients, 78 (75%) required second line treatment:
67 had pharmacotherapy, 7 a subsequent surgery, and 4
received radiotherapy as second line treatment.
Of the 121 subjects, 1 had no IGF-1 values reported,
and consequently was dropped from the main analysis.
Among the remaining 120, 79 (65.8%) had achieved bio-
chemical control during the period of observation (mean
8.8 years, median 6.1 years) and 41 (34.2%) had not. The
mean IGF-1 level at study start was 260% of upper limit
of normal (ULN) in patients who were eventually con-
trolled and 242% of ULN in those not controlled. The
mean last IGF-1 was 67.7% of ULN in controlled and
177.8% in uncontrolled patients (Table 3).
New onset comorbidities (those first reported after the
initial six months of the study period) were uncommon.
There were 6 (7.6%) new cases of hypertension and 3
(3.8%) of diabetes in controlled patients compared to 3
(7.3%) and 4 (9.8%) in uncontrolled patients. There were 7
(8.9%) cases of LVH in controlled compared to 2 (4.9%) in
uncontrolled patients. No new cases of cardiomyopathy
were observed during the study period. There was 1 case
of colon polyp or cancer in each group (1.3% controlled
vs. 2.4% uncontrolled), 6 (7.6%) cases of visual field defects
in controlled and 2 (4.9%) cases in uncontrolled patients,
with visual field defects present in all at presentation, and
not worsening during therapy (Table 4).
Considering comorbidities identified at any time dur-
ing care, rather than new onset comorbidities, in the
controlled group, 33 (41.8%) had hypertension compared
to 24 (58.5%) in the uncontrolled group. Diabetes was
observed in 20 (25.3%) of controlled compared to 17
Table 1 Baseline characteristics of 121 acromegaly patients
All
N = 121
Age, year Mean 55.4
(SD) (16.7)





























Adrenal insufficiency n 18
(%) (14.9)
Prolactin elevation n 1
(%) (0.8)
a109 patients had information about age at diagnosis
b106 patients had tumor size information
Table 2 Initial treatment
All
N = 121






Somatostatin analogues n 11
(%) (9.1)
Dopamine agonists n 5
(%) (4.1)
aIncludes patients with pre-surgical medication (≤6 months medication prior
to surgery)
b13 had presurgical medication
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(41.5%) of uncontrolled patients. LVH and cardiomyop-
athy were identified in 9 (11.4%) and 3 (3.8%) of controlled
patients compared to 4 (9.8%) and 3 (7.3%) of uncon-
trolled patients. Sleep apnea was present in 16 (20.3%) of
controlled and 11 (26.8%) of uncontrolled patients. Colon
polyps or cancer were present in 16 (20.3%) of controlled
and 8 (19.5%) of uncontrolled patients. Visual field defects
were observed in 14 (17.7%) of controlled and 6 (14.6%) of
uncontrolled patients (Table 5).
Discussion
In a large sample of acromegaly patients treated at a single
US referral center, we demonstrated a greater number of
cardiovascular and other comorbidities in biochemically
uncontrolled patients with acromegaly compared to their
controlled counterparts. We also observed that despite
the use of multiple treatment modalities by experienced
clinicians, about a third of the patients presenting to a ter-
tiary referral center remained biochemically uncontrolled
after a mean of more than eight years of treatment, dem-
onstrating the difficulty of achieving biochemical control
in some patients. Finally, we identified a higher prevalence
of hypertension, diabetes, and sleep apnea than has been
reported in other acromegaly registries [14, 15].
Cardiovascular disease in general, and LVH in particular,
are a significant cause of mortality in acromegaly [1, 5].
The biochemical basis of cardiac remodeling and subse-
quent LVH in acromegaly is not fully established but ap-
pears to result, at least in part, as a direct effect of
elevated levels of GH and IGF-1 on cardiac cells [16].
Treatment of these biochemical abnormalities improves
LVH. A review of 15 studies, most less than 1 year in dur-
ation, showed consistent reduction in LVH after biochem-
ical control of the disease [9], and subsequent studies have
had similar results [10]. Factors other than a direct hor-
monal effect on cardiac muscle may influence develop-
ment of cardiac disease. Colao et al. [17] reported that
hypertension and diabetes also correlate with the presence
of cardiomyopathy.
Hypertension (47.5%) and diabetes (30.8%) were the
most commonly observed comorbidities during the study
period, and both were more common in uncontrolled pa-
tients than in controlled patients. LVH was reported in
10.8%, and CHF in 5% of patients. Hypertension was more
Table 3 Change from initial to last IGF-1 over the study period
Controlled
N = 79; 65.8%
Uncontrolled
N = 41; 34.2%
All
N =120
Baseline IGF-1 (% of UNL) Mean 260.3 241.6 253.9
Last IGF-1 (% of UNL) Mean 67.7 177.8 105.3
Difference (last test value minus the baseline value) Mean 192.6 −63.8 −148.6
IGF-1 insulin-like growth factor I, ULN upper limit of normal
Table 4 New onset comorbid conditionsa, stratified by last observed biochemical control
Controlled
N = 79; 65.8%
Uncontrolled




Hypertension n 6 3 9
(%) (7.6) (7.3) (7.5)
Diabetes mellitus n 3 4 7
(%) (3.8) (9.8) (5.8)
Left ventricular hypertrophy n 7 2 9
(%) (8.9) (4.9) (7.5)
Cardiomyopathy or heart failure n 0 0 0
(%) (0.0) (0.0) (0.0)
Other
Sleep apnea n 0 0 0
(%) (0.0) (0.0) (0.0)
Colonic polyps or colon cancer n 1 1 2
(%) (1.3) (2.4) (1.7)
Visual field defects n 6 2 8
(%) (7.6) (4.9) (6.7)
aNew onset comorbidities were defined as evidence of condition during the study period, excluding the first 6 months comprising the baseline period
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commonly encountered in the current study than has
been reported in several European registries, and some-
what higher than a commonly cited figure of 40% [18].
For example, in a Belgian acromegaly registry of 418 pa-
tients, Bex et al. [14] reported that 39.4% of reported cases
had hypertension. From a Spanish registry of more than
1000 patients, Mestron et al. [15] reported 39.1% with
hypertension. Diabetes was less common (25.3%) in the
Belgian study and slightly more common (36.5%) in the
Spanish study [14, 15]. Hypertension and diabetes are as-
sociated with mortality in the non-acromegaly population,
although the current literature is inconsistent with regard
to the impact of biochemical acromegaly control on re-
duction in these risk factors [9]. We observed higher
prevalence of both conditions in uncontrolled compared
to controlled patients. New onset of major comorbidities
was uncommonly encountered, regardless of biochemical
control status. Hypertension (7.5%), left ventricular hyper-
trophy (7.5%), visual field defects (6.7%), and diabetes
(5.8%) were the most frequently observed new-onset co-
morbidities; all other comorbidities of interest occurred
were uncommon (<2%).
Despite the availability of multiple therapies, including
newer pharmacologic treatments, reducing serum IGF-1
levels to within the normal range remains challenging in
some patients. Overall, IGF-1 dropped substantially:
from 254% of ULN at study start to 105% of ULN at
study end. Achieving this reduction required the use of
multiple therapeutic modalities, and even with these
treatments, 34% of patients did not attain biochemical
control at the end of the study. However, even among
uncontrolled patients, IGF-1 values fell from 242% to
178% of ULN, suggesting that continued treatment over
time is likely to provide some biochemical improvement.
It is unclear with this analysis if this improvement im-
parts benefit in terms of comorbidities, in patients not
meeting a definition of biochemical control. Non-
adherence may have reduced the number of patients
who were in control at the end of the study. It is unclear
from the current data the extent to which patients were
adherent to therapy.
This study has several limitations. Firstly, despite the
relatively large sample size for a study of acromegaly,
small numbers moderate the power of statistical compari-
sons. Secondly, the results reflect care at a single institu-
tion over more than two decades. Practices have changed
significantly over that time, and the results, therefore, may
not be representative of what would be experienced were
the study to be repeated today. Thirdly, some patients
were treated elsewhere before referral to CSMC-PC. This
is a study of population of patients with complex acro-
megaly, referred for specialized tertiary or quaternary care.
Data entered in the registry reflects care from a variety of
providers both within and outside CSMC and documenta-
tion may not have been optimal. Finally, this is not a
randomized-placebo controlled study, where the study de-
sign would have required strict medication titration proto-
col and oversight until control was attained. This is a
registry where there could have been treatment interrup-
tion (e.g., insurance coverage) and unsupervised or pos-
sibly sub-optimal dose titration that may have had impact
attainment of control.
Table 5 Comorbid conditions, stratified by last observed biochemical control
Controlled
N = 79; 65.8%
Uncontrolled




Hypertension n 33 24 57
(%) (41.8) (58.5) (47.5)
Diabetes mellitus n 20 17 37
(%) (25.3) (41.5) (30.8)
Left ventricular hypertrophy n 9 4 13
(%) (11.4) (9.8) (10.8)
Cardiomyopathy or heart failure n 3 3 6
(%) (3.8) (7.3) (5.0)
Other
Sleep apnea n 16 11 27
(%) (20.3) (26.8) (22.5)
Colonic polyps or colon cancer n 16 8 24
(%) (20.3) (19.5) (20.0)
Visual field defects n 14 6 20
(%) (17.7) (14.6) (16.7)
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Conclusion
Overall, a greater number of comorbidities were ob-
served in biochemically uncontrolled patients with acro-
megaly compared to their controlled counterparts in this
single-center registry. This study indicates that about a
third of the patients remained uncontrolled after a mean
of >8 years of treatment, demonstrating the difficulty of
achieving control in some patients.
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